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Long-term evaluation of coronary 
artery calcifications in kidney 
transplanted patients: a follow up 
of 5 years
C. Alfieri1,3, L. Forzenigo2, F. Tripodi1, M. Meneghini1, A. Regalia1, D. Cresseri1 & p. Messa1,3
Coronary artery calcifications(CACs), are related to the increased cardiovascular mortality during 
kidney transplantation(KTx). Using coronary-CT performed at 1 month(T0) and 5 years(T5) after KTx 
we evaluated: (1) the prevalence of CACs; (2) the clinical and biochemical factors related to CACs; 3) the 
factors implicated with CACs progression. We evaluated 67-pts selected from the 103-pts transplanted 
in our unit between 2007 and 2008. Clinical and biochemical parameters were recorded at the time 
of pre-KTx evaluation and for five years after KTx. Coronary-CT for the Agatson score (AS) evaluation 
was performed at T0 and at T5, and CACs progression was determined. At baseline AS was 45 [0–233]. 
At T5 AS was 119 [1–413]. At T0, 69% of patients had CACs. Age and dialytic vintage were the main 
independent variables related to CACs. At T5, CACs were present in 76% of patients. Age was the only 
independent factor in determining CACs. A progression of CACs was observed in 74% of patients. They 
were older, had higher CACs-T0 and higher SBP throughout the 5-years. The presence of CACs at T0 
and age were the only independent factors in determining the CACs-progression. CACs-T0 had the best 
discriminative power for CACs progression. CACs prevalence is quite high in KTx patients; Age is strictly 
related to CACs; Age and the presence of CACs at baseline were the two major factors associated with 
the progression of CACs during the five years of follow up. CACs-T0 had the best discriminative power 
for progression of CACs.
Patients affected by chronic kidney disease (CKD) have a relevant cardiovascular risk1,2. In those patients, in fact 
the prevalence and incidence of cardiovascular (CV) events are much higher than in the general population, and 
CV events are the most common cause of death. This fact can be related to the presence of many CKD specific CV 
risk factors that contribute to make CV risk stronger in those patients3.
In the stratification of CV risk, much importance is given to vascular calcifications. In particular, coronary 
artery calcifications (CACs) are considered to be a marker of coronary heart disease.
In clinical practice, CACs evaluation can be obtained using different methods such as Electron Beam tomog-
raphy and by Multislice tomography. The two methods are similar in terms of sensitivity and specificity but, if the 
first one is characterized by high radiation exposition and is very expensive, the second one exposes patients to a 
lower quantity of radiation and is cheaper4.
In consideration of the potential high impact of CACs and of their relation with CV events and mortality, 
several clinical studies focused on the factors implicated on CACs progression have been realized5,6. In those 
studies, including mainly CKD and end stage renal disease (ESRD) patients, a higher rate of increase of CACs 
than in the general population and a relation among CACs progression, age and mineral metabolism factors have 
been reported7–9.
A small amount of data on the long term behavior of CACs in kidney transplantation (KTx) are available, 
and the few studies available are characterized by a small quantity of patients and a short observational time10–12.
Even if KTx reduces CV risk and mortality in CKD patients, in those patients CV risk remains higher than 
in the general population. So it might be important to calculate the impact of CACs in KTx and evaluate if the 
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factors related with their evolution in the long term are similar to those reported in patients affected by CKD and 
end stage renal disease.
The aim of the present study is to explore, by means of Multislice Coronary CT (CT), the prevalence of CACs 
and the rate of their modification in a cohort of 67 patents evaluated for CACs at one month and at five years after 
KTx.
In addition, clinical and biochemical factors related with CACs progression will be investigated.
Results
Cohort characteristics. Our cohort of 67 patients was composed by 37 males and 30 females. Age of the 
whole cohort was 49 [39,57] years. The main clinical characteristics of our cohort are summarized in Table 1. 
Forty-five patients received hemodialysis before KTx and 59 patients were transplanted from a deceased 
donor. Only two patients had diabetes before KTx, whereas 22 patients underwent steroid therapy before KTx. 
Immunosuppressive therapy at T0, as reported in Table 2, was composed mainly of steroids, calcineurin inhibitors 
(CNI) and anti-proliferative drugs (MMF/MPA/AZA/mTOR-I).
Hypertension was mainly treated with one or two anti-hypertensive drugs. Beta blockers were the most used 
category of anti-hypertensive drugs (data not shown).
Clinical, blood and urinary parameters at the pre-KTx evaluation, at T0 and the average values T0-T5 are 
summarized in Table 3.
During the five years of KTx, our patients didn’t show a significant decrease in renal function, whereas an 
increase in hemoglobin and serum phosphorus was found. In addition, we observed a significant reduction both 
of PTH and alkaline phosphatase levels.
Coronary artery calcifications. In Table 4 all data concerning CACs evaluation at T0 and T5 are reported.
A significant increase of AS between the two evaluations has been observed. The mean value of AS, in fact, 
increased from 45 [0–233] at T0 to 119 [1–413] (p = 0.004) at T5.
Coronary artery calcifications at T0. CACs were present in 69% of patients at baseline (CACsT0+). 
Clinical characteristics and pre-KTx biochemical exams are reported in Table 5. CACsT0+ were significantly 
older than patients without CACs at the same timepoint (CACsT0−) and had a longer dialytic vintage. No sig-
nificant differences in pre-KTx biochemical status were found between the two groups. CACsT0+ had a worse 
control of blood pressure at T0, reflecting probably a worse vascular status than CACsT0-.
Parameter
Number of patients (n) 67
Type of dialysis n(%) (No/HD/PD) 5/45/17 (8/67/25)
Dialysis vintage (mths) 50 [36,70]
Age at Tx (years) 49 [39,57]
Gender (n) (M/F) 37/30
Kind of transplant n (%) (deceased 
donor/living donor) 59/8 (88/22)
Diabetes before KTx N (%) 2 (3)
Previous steroid therapy N (%) 22 (33)
CMV IgG pos N (%) 56 (84)
HCV pos N (%) 2 (3)
HbsAg pos N (%) 0 (0)
Table 1. Clinical characteristics of the cohort studied. Footnotes: HD: Hemodialysis; PD: periotoneal diaysis; 
CMV pos: patients positive to cytomegalovirus; HCV pos: patients positive to virus of C Hepatitis; HbsAg pos: 
patients positive to HBV surface antigens.
Drug T0 T5
CyA/Tac/MMF-MPA/mTor inhibitor N (%) 4/63/64/3 (6/94/95/4) 4/44/56/10 (6/75/17/96)
Cumulative steroids during 1st yr of KTx (mg) 2715 [2605–2990] NA
Number of antihypertensive drugs (%)
0 12 8
1 39 25
2 22 42
3 22 17
>3 5 8
Table 2. Ongoing immunosuppressive and antihypertensive at T0. Footnotes: Cya: cyclosporine; Tac: 
Tacrolimus; MMF-MPA: mycophenolate; NA = not applicable.
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In multivariate analysis, age at KTx and dialysis vintage were the main independent variables related both to 
presence and to the degree of CACs at T0 (Table 6).
Coronary artery calcifications at T5. At the evaluation performed at T5, CACs were present in 76% of 
patients (CACsT5+). Clinical characteristics and the biochemical differences between CACsT5+ and those 
patients without CACs at T5 (CACsT5−) are reported in Table 7.
CACsT5+ had higher AS at baseline: 130 [9.5–343] vs 0 [0–0.75], p < 0.0001. Moreover, they were signif-
icantly older. Differently from T0, no difference in dialytic vintage between the two groups was found. Blood 
pressure control was worse in patients with CACs at T5 during the 5 years of follow up.
In multivariate analysis (Table 8), age was the only independent factor in determining both degree and the 
presence of CACs at T5.
Parameters
Pre-KTx 
examination T0 Average T0–T5 p*
SBP (mmHg) NA 135 [120–150] 135 [124–143] 0.24
DBP ((mmHg) NA 80 [80–90] 82 [77–85] 0.35
s-Creatinine (mg/dL) 8.0 [5.6–11.0] 1.41 [1.1–1.7] 1.5 [1.2–1.7] 0.09
Blood glucose (mg/dL) 91 [82–101] 74 [67–87] 79 [75–86] 0.009
Hb (g/dl) 11.3 [10.3–12.5] 10.8 [10–12] 12 [11–13] <0.0001
PTH (ng/mL) 249 [148–470] 150 [94–217] 111 [80–179] 0.01
Ca (mg/dl) 9.2 [8.8–9.6] 9.8 [9–10] 9.8 [9.5–10.2] 0.28
P (mg/dL) 5.2 [4.3–5.7] 2.3 [2–2.8] 3 [2.7–3.4] <0.0001
ALP (U/dL) 106 [62–171] 91 [68–114] 64 [54–78] 0.01
Prot-U (g/24 h) NA 0.21 [0.15–0.33] 0.19 [0.15–0.32] 0.74
Total Cholesterol (mg/dl) NA 226 [198–254] 211 [185–233] <0.0001
HDL Cholesterol (mg/dl) NA 61 [49–73] 57 [50–71] 0.004
Triglycerides (mg/dl) NA 158 [119–209] 145 [118–191] <0.0001
Table 3. Principal biochemical characteristics of our cohort at pre-Ktx evaluation at T0 and during the period 
T0–T5. Footnotes: SBP: systolic blood pressure; DBP: diastolic blood pressure; PTH: parathormone- ALP: 
Alkaline Phosphatase; Bold format: statistical significance (p < 0.05).
Parameter
AS-T0 (median [25%ile–75%ile) 45 [0–233]
p = 0.004
AS-T5 (median [25%ile–75%ile) 119 [1–413]
Categories of CACsT0 N (%)*
No CACs 21 (31)
Small quantity 7 (10)
Slight quantity 8 (12)
Moderate quantity 22 (35)
High quantity 3 (4)
Very high quantity 6 (8)
Categories of CACsT5 N (%)*
No CACs 16 (24)
Small quantity 6 (9)
Slight quantity 11 (16)
Moderate quantity 16 (25)
High quantity 11 (16)
Very high quantity 7 (10)
CACprog + N (%) 50 (74)
Table 4. Principal characteristics of CACs evaluations at T0 and T5. Footnotes: AS-T0: Agatson score at T0; 
AS-T5: Agatson score at T5; CACprog+: patients that had a progression of CACs using Sevrukov formula; 
CAC-cat+: Patients that increases their category of CACs. *CACs categories were defined according the 
indication presented in material and methods. Bold format: statistical significance (p < 0.05).
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Coronary artery calcifications progression. As represented in Fig. 1, 31% and 24% of patients had no 
CACs at T0 and T5 respectively.
At baseline, 10% and 11% of patients were in small and slight CACs category, 35%, 4% and 9% of patients were 
respectively in moderate, high and very high category.
After five years, small and slight categories were assigned to 9% and 16% of patients whereas 25% 16% and 
10% of patients had respectively moderate, high and very high CACs.
Figure 1 Using the method proposed by Sevrukov [16], a significant progression of CACs was observed in 74% 
of patients (CACprog+).
Compared to patients in whom no progression of CACs was observed (CACprog−), CACprog+ were older 
and characterized by a higher degree of CACs at baseline. In addition, they showed higher SBP during the period 
between T0 and T5. No other significant differences such as in dialytic vintage or in other biochemical parameters 
were found (Table 9).
Parameters CACT0− (n = 21) CACT0+ (n = 46) p
Age (years) 42 [36–52] 53 [41–58] 0.006
Dialysis vintage (mths) 46 [33–50] 57 [39–76] 0.03
s-Creatinine (mg/dL) 9.2 [5.9–10.2] 10.1 [6.0–11.4] 0.46
Blood glucose (mg/dL) 87 [80–93] 92 [81–103] 0.34
Pre-KTx Hb (g/dl) 11.1 [10.2–12.0] 11.4 [10.4–12.5] 0.46
Pre-Ktx PTH (ng/mL) 310 [189–618] 279 [135–470] 0.14
Pre-Ktx Ca (mg/dl) 9.3 [8.8–9.6] 9.2 [8.9–9.7] 0.72
Pre-Ktx P (mg/dL) 5.5 [4.4–6.2] 5.3 [4.5–6.0] 0.87
Pre-Ktx ALP (U/dL) 90 [63–227] 105 [58–160] 0.99
SBP T0 (mmHg) 130 [117–135] 140 [120–150] 0.03
DBP T0 (mmHg) 85 [80–90] 80 [78–90] 0.59
Table 5. Comparison between CAC-T0− and CAC-T0+. Footnotes: SBP: systolic blood pressure; DBP: 
diastolic blood pressure; PTH: parathormone- ALP: Alkaline Phosphatase; Prot-U: urinary protein excretion; 
Bold format: statistical significance (p < 0.05).
Parameter p OR IC
Dialysis vintage (mths) 0.004 1.029 1.009 1.050
Age (yrs) 0.0009 1.090 0.036 1.146
SBP T0 (mmHg) 0.11 1.029 0.993 1.066
Table 6. Multivariate analysis: Logistic regression for the event “CACT0+”. Footnotes: SBP: systolic blood 
pressure; Bold format: statistical significance (p < 0.05).
Parameters CACT5− (n = 16) CACT5+ (n = 51) p
Age (years) 37 [30–44] 53 [44–57] <0.0001
Dialysis vintage (months) 48 [37–51] 53 [36–73] 0.52
SBP T0-T5 (mmHg) 124 [118–132] 133 [127–145] 0.003
DBP T0-T5 (mmHg) 81 [79–83] 82 [77–87] 0.42
s-Creatinine T0-T5 (mg/dL) 1.3 [1.2–1.7] 1.5 [1.3–1.7] 0.49
Blood glucose T0-T5 (mg/dL) 78 [73–81] 80 [76–90] 0.14
Hb T0-T5 (g/dL) 12 [11–14] 12 [11–12.8] 0.68
PTH T0-T5 (ng/mL) 119 [77–221] 111 [80–179] 0.80
Ca T0-T5 (mg/dl) 10 [9.6–10.3] 9.7 [9.4–10] 0.15
P (mg/dL) T0-T5 3.0 [2.7–3.4] 2.9 [2.6–3.4] 0.74
ALP T0-T5 (U/dL) 68 [52–79] 64 [56–78] 0.93
Total Cholesterol T0-T5 (mg/dl) 210 [187–231] 212 [184–238] 0.78
HDL Cholesterol T0-T5 (mg/dl) 58 [51–71] 56 [49–70] 0.74
Triglycerides T0-T5 (mg/dl) 130 [108–164] 148 [123–201] 0.03
Prot-U T0-T5 (g/24 h) 0.18 [0.15–0.22] 0.20 [0.15–0.32] 0.11
Table 7. Biochemical differences between CACsT5− and CACsT5+. Footnotes: SBP: systolic blood pressure; 
DBP: diastolic blood pressure; ALP: Alkaline Phosphatase; Prot-U: urinary protein excretion; Bold format: 
statistical significance (p < 0.05).
5Scientific RepoRts |          (2019) 9:6869  | https://doi.org/10.1038/s41598-019-43216-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
The impact of immunosuppressive therapy on CAC progression was investigated, and a possible influence of 
calcineurin inhibitors treatment, in particular Tacrolimus, was evidenced. No other differences were found in the 
rest of immunosuppressive therapy and in anti-hypertensive drugs (Table 10).
In multivariate analysis, the presence of CACs at T0 and the age were the only independent factors in deter-
mining the CAC progression (Table 11).
To evaluate the discriminatory power of the three most related parameters (CACs-T0+, age and T0-T5 
SBP) in identifying those patients affected by a higher risk of CACs progression, ROC curves analyses were 
performed (Fig. 2). They demonstrated the good predictive value of CACsT0 (AUC: 0.84 ± 0.06, p < 0.001), age 
(AUC = 0.77 ± 0.07, p = 0.001) and T0-T5 SBP (AUC = 0.70 ± 0.07, p = 0.01) for identifying CACProg+ patients.
Interestingly, the insertion in the same model of CACsT0 and age considered together was followed by a 
reduction of 7% of the AUC respect the model including only CACsT0, increasing the importance of CACsT0 per 
se (without additional factors) in CACs progression. From ROC analysis, the best cut-off CACsT0 AS value able 
to identify those patients that will increase significantly CACs was 8.3 AS (sensibility: 78.0% - specificity: 88.2%).
Cardiovascular events and death. During the five years of follow up, ten patients (four in the first year 
of KTx) had a cardiovascular event (CV+). In four patients heart event (i.e.: ischemic attack- arrhythmia) 
occurred. Interestingly, all of them had a moderate/high degree of CACs both at T0 and T5- and were CACprog+ 
(p < 0.0001). No death nor graft loss have been reported.
Discussion
The first aim of our study was to evaluate in a cohort of KTx patients the prevalence of CACs at one month 
and after five years of transplantation. At T0, 69% of the cohort presented CACs and most of CAC-T0+ were 
within the category with moderate amounts of coronary calcium. These results are substantially in line with those 
reported in the literature, where a prevalence of CACs at the moment of transplantation between 35% and 70% 
is reported13,14.
In 31% of patients no CACs at baseline were found.
In our study, the correlations between CACs-T0 and some parameters before KTx have been explored. In 
agreement to the data reported in the literature, age and dialysis vintage were strongly related to the presence 
and the degree of baseline CACs15. In clinical trials, also performed by our Group, the relationship among age, 
dialysis vintage and vascular calcifications has been demonstrated also in other sites, as for example in abdomi-
nal aorta16–18. Interestingly, no correlations between pre-KTx biochemical parameters and CACs-T0 have been 
found. Some studies have also hypothesized that genetic factors might have an important role in the promotion 
of CACs development and progression both in dialysis time and after KTx19.
The correlation demonstrated between CACs and SBP at T0 probably reflects a worse cardiovascular condi-
tion of CACT0+, and therefore might be considered as a consequence, more than a determining factor of the 
calcification process.
Most of the correlations found at T0 were also confirmed at T5, when 76% of the patients had CACs. The 
subdivision into categories according to AS, evidenced an increase of the prevalence of CACs of moderate-high 
degree category from T0 to T5 evaluation. Also at T5 a correlation of age and SBP average levels with the presence 
Parameter p OR IC
Dialysis vintage (mths) 0.72 1.004 0.984 1.024
Age (yrs) 0.006 1.130 1.035 1.234
SBP T0-T5 (mmHg) 0.48 1.030 0.948 1.120
Table 8. Multivariate analysis: Logistic regression for the event “CAC-T5+”. Footnotes: SBP: systolic blood 
pressure; Bold format: statistical significance (p < 0.05).
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Figure 1. Distribution of the cohort (%) among the different categories of CACs at T0 and at T5.
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and quantity of CACs was demonstrated. Interestingly, at T5 the correlation with the dialysis vintage was not 
confirmed, and dialysis vintage was not different between CAC-Prog− and CAC-Prog+. This might indicate the 
presence of other factors implicated in the promotion of the calcification process during the life of the transplant.
In addition, it is important to underscore the direct correlation between CAC-T0 and CAC-T5. This probably 
reflects the inability of the KTx condition to reduce CACs, but rather to slow their progression respect to the 
dialysis status20. In the literature there are numerous data, frequently contradictory, concerning the effect of KTx 
on the progression of the CACs. Among them, the study of Adamidis et al. compares 20 KTx patients previously 
treated with hemodialysis with a group of 16 dialysis patients still in control. The basic evaluation shows a high 
prevalence of CACs in both groups. Also in this study close correlation between CACs and the patient’s age was 
described. In the follow-up (mean of 16 months) a slower progression of the calcific process in the KTx group 
was documented21. In another study, conducted on 281 patients, Marechal et al. were not able to demonstrate a 
benefit of the transplantation on coronary calcification. The main results, in fact, report that the progression is 
present mainly within the first four years of transplantation and that the baseline quantity of calcifications is an 
independent determinant of CACs progressionxx.
The second aim of our study was to evaluate during follow-up the prevalence of CACs progression and to try 
to identify the factors related with this event. As in other studies, for the identification of patients in which the 
amount of CACs increased, we used the formula proposed by Sevrukov22. The progression of CACs was observed 
in 74% of patients, with an increase of the percentage of subjects who fell into the categories with the highest 
AS. Again, also CACs progression was significantly correlated to age, to a higher Agatston score at T0 as well as 
to a higher average SBP during the five years between the TC evaluations. Interestingly, no significant correla-
tions were found with the average values of biochemical parameters obtained in the five years, including mineral 
metabolism parameters, and this allows us to assume that once the calcification process began, self-maintained 
Parameters CACProg− (n = 17) CACProg+ (n = 50) p
CACs-T0 (AS) 0 [0–2] 129 [9.4–265] <0.0001
Age (years) 39 [30–46] 53 [43–57] 0.001
Dialysis vintage (months) 49 [40–60] 53 [36–72] 0.76
SBP T0-T5 (mmHg) 124 [118–133] 133 [127–145] 0.01
DBP T0-T5 (mmHg) 82 [79–84] 82 [77–88] 0.55
s-Creatinine T0-T5 (mg/dL) 1.4 [1.2–1.7] 1.5 [1.3–1.7] 0.47
Blood glucose T0-T5 (mg/dL) 79 [74–82] 79 [75–88] 0.33
Hb T0-T5 (g/dL) 12 [11–14] 12 [11–13] 0.77
PTH T0-T5 (ng/mL) 103 [77–202] 79 [75–88] 0.33
Ca T0-T5 (mg/dl) 10 [9.6–10.3] 9.7 [9.4–10] 0.16
P (mg/dL) T0-T5 3 [2.7–3.5] 3 [2.7–3.3] 0.49
ALP T0-T5 (U/dL) 70 [52–81] 64 [56–78] 0.62
Total Cholesterol T0-T5 (mg/dl) 221 [179–235] 211 [190–228] 0.86
HDL Cholesterol T0-T5 (mg/dl) 57 [47–72] 57 [50–70] 0.90
Triglycerides T0-T5 (mg/dl) 131 [97–172] 147 [121–194] 0.20
Prot-U T0-T5 (g/24 h) 0.18 [0.15–0.23] 0.19 [0.15–0.34] 0.15
Table 9. Differences between CACProg− and CACProg− +. Footnotes: SBP: systolic blood pressure; DBP: 
diastolic blood pressure; ALP: Alkaline Phosphatase. Prot-U: urinary protein excretion; Bold format: statistical 
significance (p < 0.05).
Parameters CAC-Prog− (n = 17) CAC-Prog+ (n = 50) p
Gender (n) (M/F) 7/10 20/30 0.17
Type of dialysis n (%) (No/HD/PD) 1/12/4 (7/70/23) 12/34/4 (24/68/8) 0.95
Kind of transplant n (%) (deceased donor/living donor) 14/3 (82/12) 45/5 (90/10) 0.40
Calcineurin Inhibitors therapy T5 n (%) (No/Cya/FK) 1/3/13 (7/17/76) 10/1/39 (20/2/78) 0.04
Steroid Therapy T5 n (%) (No/Yes) 1/16 (6/94) 1/49 (2/98) 0.42
mTor-i therapy T5 n (%) (No/Yes) 16/1 (94/6) 39/11 (78/22) 0.20
MMF therapy T5 n (%) (No/Yes) 0/17 (0/100) 3/47 (6/94) 0.39
Number of antihypertensive drugs (%)
0 5 8
0.69
1 36 18
2 43 38
3 11 28
>3 5 8
Table 10. Differences between CACProg− and CACProg− + in therapy.
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processes, irrespective of metabolic-mineral status, might be present. However, the lack of these correlations 
could also be attributed to the limited period of follow-up, although five years is a fairly long time compared to 
many studies in the literature.
In 2009, Abedi et al. explored the effect of renal transplantation on the calcium scores of coronary arteries 
among 31 hemodialysis patients. They demonstrated a significant reduction of CACs after six months of KTx 
respect pre-KTx evaluation. In addition, a significant linear correlation between AS and iPTH and Ca-P product 
reduction was found11. These results might seem to be partially in contrast with ours. It is important however to 
underscore that some methodological differences are present between the two studies. In our study, that included 
a higher number of cases, the second CACs evaluation has been performed significantly later after KTx (five 
years). In addition, CACs progression was defined differently in the two studies and by means of two different 
methods. As in Abedi et al. study, according to our results CAC-Prog + patients showed a tendency (not sta-
tistically significant after the application of not-parametrical tests) to have lower levels of PTH. Of note, in our 
study, considering the high variability of PTH levels, the T0-T5 average levels, and not the single PTH level at the 
moment of the second evaluation, have been considered. The same was done for the other parameters of mineral 
metabolism.
With the aim to explore the discriminating power for CACs progression of the three most related parameters, 
ROC analysis was performed. ROC analysis confirmed the good correlations already evidenced for all the three 
parameters, and identified the presence of CACs at T0 as the strongest discriminating factor for CACs progres-
sion, with an AUC of 0.84 and a threshold value for CACsT0 AS of 8.4.
During the five years of follow-up, 10 of our patients developed cardiovascular events. All these patients were 
both at T0 and T5 in moderate/high degree categories, as well as in the group of subjects in which CAC pro-
gression was observed. Even if obtained in a small cohort of patients, this result, associated to those evidenced 
Parameter p OR IC
CACs-T0+ 0.0007 20.5 3.55 118.2
Dialysis vintage (mths) 0.19 0.984 0.960 1.008
Age (yrs) 0.05 1.093 1.0 1.19
SBP T0-T5 (mmHg) 0.75 0.98 0.90 1.07
Table 11. Multivariate analysis: Logistic regression for the event “CAC-Prog+”. Footnotes: SBP: systolic blood 
pressure; Bold format: statistical significance (p < 0.05).
Figure 2. ROC curves for the event “CAC-Prog+”. (A) Dependent variable- CACsT0. (B) Dependent variable- 
Age at KTx. (C) Dependent variable- SBP T0-T5.
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by ROC curves, could stress the importance of the accurate cardiovascular study before KTx and of the regular 
cardiovascular follow up to identify those patients at higher cardiovascular risk.
The principal limitation of our study is the small number of patients, which does not allow a proper assess-
ment of the different distribution of patients within the categories of AS and does not give the opportunity to 
evaluate deeply the factors related to the change of category.
In consideration of the main purposes of our work, we can conclude that in our cohort of KTx patients:
•	 the prevalence of CACs at the time of transplantation is quite high;
•	 that prevalence is also confirmed in the subsequent assessment performed five years after kidney transplanta-
tion, in which an increase in patients with coronary calcifications was demonstrated;
•	 there is a strict relation between CACs and age, both at T0 and T5;
•	 Age and the presence of CACs at baseline are the two major factors associated with the progression of coro-
nary calcifications during the five years of follow up, and among them the amount of CACs at T0 was found to 
have the best discriminative power among patients with progression of coronary calcifications.
The results obtained in our study validate the need to consider, in specific cases, the amount of coronary cal-
cium in pre-transplant evaluation of patients on dialysis.
This approach could be useful to identify those patients at increased cardiovascular risk and to set up a com-
prehensive evaluation in the post-transplant time.
Material and Methods
Cohort characteristics. A total of 67 patients (M = 37), randomly selected from the 103 patients trans-
planted in our Unit between January 2007 and December 2008 have been examined. Clinical and biochemical 
characteristics of studied patients at baseline were not different to those of patients excluded from the study.
At the first month (T0) and after five years of KTx (T5), each patient underwent a thoracic tomography for the 
evaluation of CACs.
After KTx all patients were followed according to routine clinical indications of our Department.
The protocol was approved by the Ethics Committee of Fondazione IRCCS Ca’Granda Ospedale Maggiore 
Policlinico of Milan, and was conducted according to the ethical principles of the Helsinki Convention, and each 
patient signed an informed consent. No organs/tissues analysed for this study were procured from prisoners.
Biochemical evaluations. Biological samples were collected in our Department from each patient after 
12 hours of fasting, and all biochemical analyses were performed in the same laboratory at our Institution. 
Biochemical data observed at the moment of the pre-transplant examination and at T0 were recorded. To take 
into account the global exposition of patients during the five years of follow up, between T0 and T5 clinical and 
biochemical parameters were recorded, and considered in statistical analysis as average values.
Jaffe method was used to dose serum creatinine, whereas daily urinary protein excretion (Prot-U) was deter-
mined by immunoturbidimetric method.
Parathormone (PTH) levels were quantified using ECLIA (ImmunoAssay in ElettroChemiLuminescent) 
method by Roche by means of modular analytics E170. The Measure range was 1.20–5000 pg/mL The Conversion 
was: pg/mLx0.106 = pmol/L. Normal range: 15–65 pg/ml.
All the other biochemical parameters were evaluated according to routine methodology used in our central 
laboratory.
Computed tomography and Agatson Calcium Score quantification. Radiological images were 
acquired with a scanner Somaton Definition Dual Source 64 slices.
Briefly, the patient, supine on the tomography table was prepared to be ECG monitored. The optimal cardiac 
frequency for a good acquisition of the images was set at 50–60 bpm. The sequential acquisition of default was 
performed automatically by the scanner during the interval ECG R-R, to evaluate images only in one precise 
phase of the cardiac cycle. The radiant dose to which patients were exposed was around 1.5–2 mSvs, more con-
tained in comparison to the examinations with retrospective gating (4–7 mSvs)23.
After the scan, the acquired images were re-elaborated, using specific software Siemens, for the measurement 
of the CACs according to the method of Agatson24. In particular, the software used identifies all the pixels with 
density> 130 HUs and attributes them a code color on the next elaborated images. The radiologist identifies the 
center of the coronary calcification attributing a different color according to the center of the calcific plate, dis-
tinguishing common coronary, descending anterior, circumflex, right coronary, and descending back coronary 
(Fig. 3).
According to Agatson method, the software multiplies the ampleness of the identified area of at least 0.52 mm2 
(2 pixels) with density >130 UH for one of the following factors25:
•	 1 for values from 130 to 199 UH;
•	 2 for values from 200 up to 299 UH;
•	 3 for values from 300 to 399 UH;
•	 4 for values >400 UH;
The total value of the calcification is obtained by the sum of the scores of the single areas identified in every 
coronary artery applying her two specific equations for Agatson score (AS) and volumetric score (VS).
These measurements are effected on the whole tree coronary and they allow to distinguish four degrees of 
gravity for a progressive increase of the quantity coronary calcium:
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•	 Score 0–1, absence of CACs
•	 Score 1–10, small quantity;
•	 Score 11–100, slight quantity;
•	 Score 101–400, moderate quantity;
•	 Score 401–1000, high quantity
•	 Score >1000, very high quantity.
The method proposed by Sevrukov for CACs progression determination was used. According to this method, 
in presence of two different evaluations of CACs:
•	 in subjects with detectable CACs at baseline, the smallest statistically significant interval change indicative of 
CACs progression is defined by the formula (4.93 ×√baseline CACs)
•	 in subjects with a baseline CACs = 0, a follow-up CACs >11.6 indicates progression26.
Definition and data collection of cardiovascular events. The following cardiovascular events have 
been considered for this paper: ischemic heart attacks (STEMI and N-STEMI), arrhythmias, brain ischemia and 
hemorrhages. All the cardiovascular events were reported in written clinical records by the transplant medical 
doctors of our Unit.
Statistical analysis. In statistical analysis, continuous variables were expressed as median value [25%ile; 
75%ile] and were log transformed if they had a skewed distribution.
Differences among groups were determined by Student’s t test, Mann-Whitney, Kruskal-Wallis test and 
ANOVA, where indicated.
Differences among percentages were determined by χ2 or Fisher test.
Linear regression and logistic regression were employed in order to perform uni-variated and multi-variated 
analysis respectively.
Clinical and biochemical parameters were considered as the value recorded at the moment of the first CAC 
evaluation (T0) and the average values recorded during the five years of follow up (T0-T5).
Patients with AS <1 were considered as not affected by CACs.
The discriminating power of different parameters for identify CACProg+ patients was analysed by means of 
Receiver Operating Characteristic (ROC) curves.
Statistical analysis was performed using software Statistica® version 10 and SPSS version 20® and significance 
was set for p values < 0.05.
Other statements. We declare that no organs/tissues analysed for this study were procured from prisoners. 
If needed, data are available in anonymous form.
Ethical approval. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Informed consent. Informed consent was obtained from all individual participants included in the study.
References
 1. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, 
and hospitalization. N Engl J Med 351(13), 1296–305 (2004).
 2. Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. & Smith, D. Longitudinal follow-up and outcomes among a population with 
chronic kidney disease in a large managed care organization. Arch Intern Med 164(6), 659–63 (2004).
Figure 3. Calcification of anterior descendent coronary artery detected using TC (A). Coronary arterial 
calcifications evaluated using Agatson score (B).
1 0Scientific RepoRts |          (2019) 9:6869  | https://doi.org/10.1038/s41598-019-43216-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 3. Marenzi, G., Cosentino, N. & Guastoni, C. How to balance risks and benefits in the management of patients with coronary artery 
disease. J Nephrol. 28(4), 403–413 (2015).
 4. Detrano, R. C. et al. Coronary calcium measurements: effect of CT scanner type and calcium measure on rescan reproducibility. Aug 
236(2), 477–84 (2005).
 5. Di Iorio, B. et al. INDEPENDENT Study Investigators. Sevelamer versus calcium carbonate in incident hemodialysis patients: results 
of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62(4), 771–8 (2013).
 6. Raggi, P. Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal 
disease. Nephrol Dial Transplant 17(2), 332–5 (2002).
 7. Russo, D. et al. Progression of coronary artery calcification in predialysis patients. Am J Nephrol. 27(2), 152–8 (2007).
 8. Russo, D. et al. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving 
dialysis. Kidney Int 80(1), 112–8 (2011).
 9. Goodman, W. G. et al. Vascular Calcification Work Group. Vascular calcification in chronic kidney disease. Am J Kidney Dis 43(3), 
572–9 (2004).
 10. Roe, P., Wolfe, M., Joffe, M. & Rosas, S. E. Inflammation, coronary artery calcification and cardiovascular events in incident renal 
transplant recipients. Atherosclerosis 212(2), 589–94 (2010).
 11. Abedi, S. A., Tarzamni, M. K., Nakhjavani, M. & Bohlooli, A. Effect of renal transplantation on coronary artery calcification in 
hemodialysis patients. Transplantation Proc 41(7), 2829–31 (2009).
 12. Schankel, K. et al. Determinants of Coronary Artery Calcification Progression in Renal Transplant Recipients. Am J Transplant 7(9), 
2158–2164 (2007).
 13. Mazzaferro, S. et al. Progression of coronary artery calcification in renal transplantation and the role of secondary 
hyperparathyroidism and inflammation. Clin J Am Soc Nephrol. 4(3), 685–90 (2009).
 14. Stróżecki, P. et al. Coronary artery calcification and large artery stiffness in renal transplant recipients. Adv Med Sci. 60(2), 240–5 
(2015).
 15. Goodman, W. G. et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N 
Engl J Med. 18(342(20)), 1478–83 (2000).
 16. Connolly, G. M., Cunningham, R., McNamee, P. T., Young, I. S. & Maxwell, A. P. Elevated Serum Phosphate Predicts Mortality in 
Renal Transplant Recipients. Transplantation 15(87(7)), 1040–4 (2009).
 17. Meneghini, M. et al. Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney 
transplantation. Transplantation 96(1), 42–8 (2013).
 18. Peeters, M. et al. MASTERPLAN Study Group. Abdominal aortic calcification in patients with CKD. J Nephrol 30(1), 109–118 
(2017).
 19. Maréchal, C. et al. Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J 
Kidney Dis 59(2), 258–69 (2012).
 20. Moe, S. M. et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 19(9), 2387–93 
(2004).
 21. Adamidis, K. et al. Progression of coronary artery calcification after kidney transplantation. Ren. Fail. 35(8), 1075–8 (2013).
 22. Sinnott, B., Syed, I., Sevrukov, A. & Barengolts, E. Coronary calcification and osteoporosis in men and postmenopausal women are 
independent processes associated with aging. Calcif Tissue Int 78(4), 195–202 (2006).
 23. Wrong O Nephrocalcinosis, in: DAvidsen, A. M., Cameron, J. S. & Grunfeld, J. P. Ed. Oxford University Press 1998; 1375–96
 24. van der Bijl, N. et al. Assessment of Agatston Coronary Artery Calcium Score Using Contrast-Enhanced CT Coronary Angiography. 
AJR Am J Roentgenol. 195(6), 1299–1305 (2010).
 25. Bargnoux, A. et al. Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin 
levels. Am J Transplant 9(11), 2571–9 (2009).
 26. Sevrukov, A., Bland, J. & Kondos, G. Serial electron beam CT measurements of coronary artery calcium: Has your patient’s calcium 
score actually changed? AJR. AJR Am J Roentgenol 185(6), 1546–53 (2005).
Author Contributions
M.P. and F.L. were responsible for study concept and design A.C., T.F., M.M., R.A. and C.D. wrote the main 
manuscript. F.L. was responsible for radiological evaluations; A.C. performed the statistical analyses.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
